Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 12/20 | 0.76 |
| ▸ | ELOC | Q15369 | 2/20 | 0.76 |
| ▸ | ELOB | Q15370 | 2/20 | 0.76 |
| ▸ | EGFR | P00533 | 4/20 | 0.64 |
| ▸ | BRD4 | O60885 | 3/20 | 0.62 |
| ▸ | NAMPT | P43490 | 4/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22325294 | 1.00 | VHL (0.76) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL21308313 | 1.00 | VHL (0.76) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL29290867 | 1.00 | VHL (0.76) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL24201266 | 1.00 | VHL (0.76) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL22186170 | 1.00 | VHL (0.76) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL24201263 | 1.00 | VHL (0.76) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL22186168 | 0.99 | VHL (0.75) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL22325241 | 0.99 | VHL (0.75) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL22325243 | 0.99 | VHL (0.75) | VHLELOCELOBEGFRBRD4 | |
| SCHEMBL31228127 | 0.97 | VHL (0.73) | VHLELOCELOBEGFRBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137742-A1 | COMPOUNDS AND COMPOSITIONS AS FGFR3 DEGRADERS AND USES THEREOF | BLUEPRINT MEDICINES CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20200207753-A1 | Tripartite Androgen Receptor Eliminators, Methods and Uses Thereof | SPG THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207753-A1 | Tripartite Androgen Receptor Eliminators, Methods and Uses Thereof | AR, ESRRA, ESRRB | VHL 619/4885ELOC 1935/4885ELOB 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.